Cytotoxicity of expanded CIK cells from lymphoma patients against autologous lymphoma cell in presence of anti CD20 antibody. (A) Cytotoxicity of patient-derived CIK cultures against autologous lymphoma cells in the presence of mAbs. Target cells were labeled with calcein-AM and incubated for 4 hours with effector cells at effector-to-target ratios of 30:1, 10:1, and 5:1. The killing assay was done with no added antibody (black columns), 1 μg/mL rituximab (striped columns), 1 μg/mL GA101 (gray columns), or 1 μg/mL trastuzumab (open columns). Data are expressed as mean percentage ± SD of 3 independent experiments. (B) CD107a mobilization: 3 expanded CIK cultures from lymphoma patients and each autologous patient-derived lymphoma's cells were mixed at a 1:1 ratio for 3 hours with 1 μg/mL of rituximab or GA101. Surface CD107a marker expression was determined using flow cytometry with gating on CD3⁻/CD56⁺ NK lymphocytes. Mean percentage of CD107a⁺/CD3⁻/CD56⁺ cells and SDs are shown (n = 3).